KaliVir Immunotherapeutics
Develops oncolytic immunotherapies for patients with advanced solid tumors
$14MSeries A
Role not disclosedCK
Company K Partners
Activity from announced rounds
All recorded activity
- Rounds participated in
- 2
- Confirmed lead rounds
- — 2 roles undisclosed
- New companies
- 2 First participation on record · 0 follow-on
- Funding in participating rounds
- $149M 2 disclosed · full round size, not this investor’s share